In-Vitro Related Topics 
Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: In-vitro T-cell activation. Immatics is the leading patent filer in in-vitro T-cell activation.
Medical Xpress
MAY 5, 2023
Among patients with recurrent implantation failure during in vitro fertilization, treatment with prednisone does not improve the live birth rate versus placebo, according to a study published in the May 2 issue of the Journal of the American Medical Association (JAMA).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
SEPTEMBER 16, 2022
A new In Vitro Pharmacology Working Group to accelerate regulatory submissions has been created by the Pistoia Alliance, a global advocate for greater collaboration in life sciences R&D. The post In Vitro Pharmacology Working Group to address data standards appeared first on Drug Discovery World (DDW).
Drug Discovery World
MARCH 21, 2023
The In Vitro Diagnostic Regulation (IVDR) came into effect in May 2022. The number of clinical trials delayed is expected to run into the hundreds, affecting up to 42,200 patients over the next three years, according to a survey run by EFPIA. However, this process is currently complex and uncoordinated.
Pharmaceutical Technology
APRIL 7, 2023
In vitro data of EDP-323 showed a significant reduction in RSV replication with picomolar potency in primary human bronchial epithelial cells against RSV A and B. Enanta Pharmaceuticals has secured the US Food and Drug Administration’s (FDA) fast track designation for EDP-323 to treat respiratory syncytial virus (RSV).
Medical Xpress
SEPTEMBER 30, 2022
A study by researchers at Institute of Environmental Medicine shows that in vitro new approach methodologies (NAMs) can be a useful tool to improve cancer risk assessment (CRA) strategies in the context of complex environmental mixtures as such air pollution.
The Pharma Data
MARCH 3, 2023
Findings show that guselkumab is able to dose-dependently bind to CD64+ a myeloid cells, 1 the predominant source of IL-23-driven inflammation in the gut. 2,b Data comprise one of Janssen’s 22 oral and poster presentations at the 18 th Congress of the European Crohn’s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark, March 1-4.
Expert insights. Personalized for you.
130 
Let's personalize your content